

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Respiriology

ESPS manuscript NO: 20109

Title: β 2-adrenoceptor in obstructive airway diseases: Agonism, antagonism or both?

Reviewer's code: 02446061

Reviewer's country: Mexico

Science editor: Fang-Fang Ji

Date sent for review: 2015-05-28 22:24

Date reviewed: 2015-06-29 01:55

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear authors: Your manuscript is centered in a attractive topic. Some documents are related to this topic, but I think your manuscript is a good compilation about recent advances and the feasibility to impact in the clinical fields. Two points are relevant for checking before to consider your manuscript in WJR: 1. Please check the adequate expresion of the content. In other words, please check the use of english language and the meaning of intented sentences. (An example, I suggest: Obstructive airway disease is a complex entity including several maladies characterized by bronchoconstriction and abnormal airway inflammation.) 2. I suggest you the inclusion of some mechanisms probably involved in the 'benefitful-action' of beta-blockers (as is mentioned in your references 37,58 and 59). Please read the following documents and analyze the last sections of your manuscript as well as your conclusions (and probably some of your figures). 1. Recent structural advances of β 1 and β 2 adrenoceptors yield keys for ligand recognition and drug design. Soriano-Ursúa MA, Trujillo-Ferrara JG, Correa-Basurto J, Vilar S. J Med Chem. 2013 Nov 14;56(21):8207-23. 2. β -Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study. Loth DW, Brusselle GG, Lahousse L, Hofman A, Leufkens HG, Stricker BH. Br J Clin Pharmacol. 2014 Jan;77(1):190-200. 3.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Applying the risk of bias tool in a systematic review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma. Hartling L, Bond K, Vandermeer B, Seida J, Dryden DM, Rowe BH. PLoS One. 2011 Feb 24;6(2):e17242. 4. Clinical implications of recent insights into the structural biology of beta2 adrenoceptors. Amezcua-Gutierrez MA, Cipres-Flores FJ, Trujillo-Ferrara JG, Soriano-Ursua MA. Curr Drug Targets. 2012 Sep 1;13(10):1336-46. Best regards, Reviewer

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Respiriology

ESPS manuscript NO: 20109

Title: β 2-adrenoceptor in obstructive airway diseases: Agonism, antagonism or both?

Reviewer's code: 02535483

Reviewer's country: Finland

Science editor: Fang-Fang Ji

Date sent for review: 2015-05-28 22:24

Date reviewed: 2015-06-04 17:40

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

dear Sirs, The manuscript summarizes the use of 2-agonist drugs in obstructive airway disease; their benefits and potential risks. It also discuss the interaction of 2-agonist and patients' other inflammatory diseases like cardiovascular disease. The latter topic is very interesting since the western population gets older and multiple diseases / multiple medications are likely to more common. Only few article have addressed the latter topic. The manuscript is very well written and language is good. The references are widely and carefully selected consisting the major studies on the area. Only thing that I was missing was the statistics on the use of beta blockers as well as the frequencies of diagnosed 'pure' obstructive airway disease, airway disease + cardiovascular disease and 'pure' cardiovascular disease, in order to understand how common these are issues now.